StreetInsider.com News Articles

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Wed, 09 Sep 2026 09:00:00 -0400

Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centers

ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated financing solutions. The partnership will support access to FemaSeed Complete, an in-office intratubal insemination solution designed

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Wed, 09 Sep 2026 09:00:00 -0400

Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centers

Femasys partners with UNC Health to expand fertility portfolio

Wed, 26 Aug 2026 09:01:16 -0400

Femasys Inc. (NASDAQ: FEMY) announced a partnership with UNC Health to introduce its fertility diagnostics and treatment products across UNC Health's OB/GYN practice locations in North Carolina, according to a company press release.

The agreement covers FemVue, a fallopian tube patency assessment tool using ultrasound; SpermVue, an at-home male fertility screening option; and FemaSeed Complete, an in-office intratubal insemination solution intended as a first-line fertility treatment. OB/GYNs within the UNC Health system will be able to offer these products without requiring referral to a fertility specialist or outside laboratory.

Femasys CEO and Founder Kathy Lee-Sepsick said the company launched its OB/GYN commercial

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Wed, 26 Aug 2026 09:00:00 -0400

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue^® fertility evaluation and FemaSeed as a first-line treatment option --

ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue™, together with FemaSeed Complete,

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Wed, 26 Aug 2026 09:00:00 -0400

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue^® fertility evaluation and FemaSeed as a first-line treatment option --

Form D FEMASYS INC

Thu, 20 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260820/26956397.html

Form D FEMASYS INC

Thu, 20 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260820/26956397.html

FDA approves modular PMA pathway for Femasys FemBloc device

Wed, 19 Aug 2026 09:00:13 -0400

Femasys Inc. (NASDAQ: FEMY) announced that the U.S. Food and Drug Administration has approved a modular premarket approval application (PMA) pathway for FemBloc, the company's investigational non-surgical permanent birth control technology.

The modular PMA approach allows the FDA to review key components of the submission before final clinical data are available. FemBloc is currently being studied in the FINALE pivotal trial and has already received regulatory approvals in Europe, the United Kingdom, and New Zealand.

"FDA approval of the modular PMA pathway provides a clear and efficient framework for advancing FemBloc toward U.S. approval, allowing key components of the submission to be

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Wed, 19 Aug 2026 09:00:00 -0400

-- Modular PMA pathway advances FemBloc toward potential U.S. approval while Femasys builds commercial infrastructure across its reproductive health portfolio --

ATLANTA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that the U.S. Food and Drug Administration has approved the Company’s modular premarket approval application (PMA) pathway for FemBloc, its investigational non-surgical permanent birth control technology in the United States. FemBloc is approved for

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Wed, 19 Aug 2026 09:00:00 -0400

-- Modular PMA pathway advances FemBloc toward potential U.S. approval while Femasys builds commercial infrastructure across its reproductive health portfolio --

Femasys Inc. (FEMY) PT Lowered to $10 at Lake Street

Tue, 18 Aug 2026 10:49:40 -0400

Lake Street analyst Benjamin Haynor lowered the price target on Femasys Inc. (NASDAQ: FEMY) to $10.00 (from $30.00) while maintaining a Buy rating.

Form SCHEDULE 13D FEMASYS INC Filed by: Nantahala Capital Partners Limited Partnership

Mon, 17 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26938380.html

Form SCHEDULE 13D FEMASYS INC Filed by: Nantahala Capital Partners Limited Partnership

Mon, 17 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26938380.html

Femasys Inc. (FEMY) Misses Q2 EPS by 20c

Mon, 17 Aug 2026 06:39:37 -0400

Femasys Inc. (NASDAQ: FEMY) reported Q2 EPS of ($1.33), $0.20 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $330 thousand versus the consensus estimate of $1.16 million.

For earnings history and earnings-related data on Femasys Inc. (FEMY) click here.

Form 10-Q FEMASYS INC For: Jun 30

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931419.html

Form 10-Q FEMASYS INC For: Jun 30

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931419.html

Form 8-K FEMASYS INC For: Aug 14

Fri, 14 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26930718.html

Form 8-K FEMASYS INC For: Aug 14

Fri, 14 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26930718.html

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

Fri, 14 Aug 2026 16:05:00 -0400

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed^® fertility portfolio and advancement of the FemBloc^® clinical and regulatory program toward U.S. approval --

ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

Corporate Highlights from 2Q 2026 to date

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

Fri, 14 Aug 2026 16:05:00 -0400

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed^® fertility portfolio and advancement of the FemBloc^® clinical and regulatory program toward U.S. approval --

ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

Corporate Highlights from 2Q 2026 to date
- Form SCHEDULE 13G FEMASYS INC Filed by: Rosalind Advisors, Inc.
  
  Fri, 14 Aug 2026 10:50:00 -0400
  si-local-file:///var/storage/secattach/20260814/26926800.html
  
  Form SCHEDULE 13G FEMASYS INC Filed by: Rosalind Advisors, Inc.
  
  Fri, 14 Aug 2026 10:50:00 -0400
  si-local-file:///var/storage/secattach/20260814/26926800.html
  
  Femasys Inc. (FEMY) PT Lowered to $10 at Maxim Group
  
  Fri, 14 Aug 2026 08:32:07 -0400
  Maxim Group analyst Jason McCarthy lowered the price target on Femasys Inc. (NASDAQ: FEMY) to $10.00 (from $30.00) while maintaining a Buy rating.
  
  Femasys secures new patents for FemBloc polymer in U.S. and abroad
  
  Wed, 12 Aug 2026 09:03:20 -0400
  
  Femasys Inc. (NASDAQ: FEMY) announced the issuance of patents in the United States and several international markets covering the blended polymer component of its FemBloc non-surgical permanent birth control technology, according to a company press release dated Aug. 12, 2026.
  The newly issued patents include U.S. Patent No. 12606719, along with patents in Japan, South Korea, Brazil, Hong Kong, India, and multiple European countries under a European Patent Office grant. The European coverage extends to Belgium, Denmark, Germany, France, Ireland, Spain, Great Britain, Italy, Luxembourg, the Netherlands, Sweden, Turkey, and Switzerland.
  These patents cover FemBloc's blended polymer, which is placed into both
  
  Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
  
  Wed, 12 Aug 2026 09:00:00 -0400
  
  -- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution --
  
  ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company’s non-surgical permanent birth control technology. These

StreetInsider.com News Articles

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Femasys partners with UNC Health to expand fertility portfolio

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Form D FEMASYS INC

Form D FEMASYS INC

FDA approves modular PMA pathway for Femasys FemBloc device

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Femasys Inc. (FEMY) PT Lowered to $10 at Lake Street

Form SCHEDULE 13D FEMASYS INC Filed by: Nantahala Capital Partners Limited Partnership

Form SCHEDULE 13D FEMASYS INC Filed by: Nantahala Capital Partners Limited Partnership

Femasys Inc. (FEMY) Misses Q2 EPS by 20c

Form 10-Q FEMASYS INC For: Jun 30

Form 10-Q FEMASYS INC For: Jun 30

Form 8-K FEMASYS INC For: Aug 14

Form 8-K FEMASYS INC For: Aug 14

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

Form SCHEDULE 13G FEMASYS INC Filed by: Rosalind Advisors, Inc.

Form SCHEDULE 13G FEMASYS INC Filed by: Rosalind Advisors, Inc.

Femasys Inc. (FEMY) PT Lowered to $10 at Maxim Group

Femasys secures new patents for FemBloc polymer in U.S. and abroad

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents